Skip to main content
Clinical Trials/NCT01535404
NCT01535404
Terminated
Not Applicable

Right Versus Left Apical Transvenous Pacing for Patients With Preserved Left Ventricular Systolic Function (RIVELA) Study

Haran Burri, MD6 sites in 2 countries36 target enrollmentJanuary 2012
ConditionsBradyarrhythmia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bradyarrhythmia
Sponsor
Haran Burri, MD
Enrollment
36
Locations
6
Primary Endpoint
Reduction in LVEF
Status
Terminated
Last Updated
9 years ago

Overview

Brief Summary

The purpose of this study is to compare chronic (1-year) effects on left ventricular ejection fraction resulting from transvenous pacing of the right ventricular apex (RVA) versus the left ventricular apex (LVA) in patients with preserved or mildly reduced left ventricular systolic function (>= 45%).

Detailed Description

It is well established that chronic right ventricular apical pacing has an adverse effect on left ventricular systolic function. An alternative is pacing the left ventricular apex, which has shown more favourable results in terms of left ventricular pump function than the RVA in small series. The left ventricular apex may be paced via the coronary sinus tributary (e.g. in the anterior cardiac vein). Our study will compare effects of these two pacing sites on left ventricular ejection fraction measured by 3D-echocardiography.

Registry
clinicaltrials.gov
Start Date
January 2012
End Date
May 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Haran Burri, MD
Responsible Party
Sponsor Investigator
Principal Investigator

Haran Burri, MD

Assoc. Prof.

University Hospital, Geneva

Eligibility Criteria

Inclusion Criteria

  • Requirement for ventricular pacing according to current guidelines (including chronic atrial fibrillation)
  • Anticipated \>=50% daily ventricular pacing
  • LVEF \>=45% as evaluated by 2D-echocardiography, 3D-echocardiography, magnetic resonance imaging or by radionuclide/contrast ventriculography
  • Minimum age of 18 years, and at least 1 year life expectancy

Exclusion Criteria

  • Prior tricuspid valve replacement (annuloplasty is permitted)
  • Intrinsic rhythm \< 30bpm
  • Patients with permanent atrial fibrillation who undergo ablation of the atrioventricular node.
  • Echocardiographic window of insufficient quality for measuring LVEF
  • Life expectancy of \< 1year
  • Pregnancy (women of childbearing potential will undergo pregnancy testing)
  • Unable of unwilling to sign a patient informed consent form

Outcomes

Primary Outcomes

Reduction in LVEF

Time Frame: baseline to one year

Secondary Outcomes

  • Change in left ventricular end-systolic and end-diastolic volumes(one year)
  • Dyssynchrony evaluation during RV and LV pacing(one year)
  • Change in tricuspid regurgitation severity, if any(one year)
  • Change in mitral regurgitation severity, if any(one year)
  • Incidence of device-related complications(one year)
  • Success rate of autocapture algorithm for left-and right-ventricular pacing(one year)
  • Mortality and all cause hospitalization(one year)
  • Reduction of LVEF at 1 year compared to baseline according to the following pre-specified subgroups: a) initial LVEF, b) gender, c)etiology (coronary artery disease, nonischemic cardiomyopathy)(one year)

Study Sites (6)

Loading locations...

Similar Trials